<SEC-DOCUMENT>0001193125-24-177075.txt : 20240710
<SEC-HEADER>0001193125-24-177075.hdr.sgml : 20240710
<ACCEPTANCE-DATETIME>20240710092610
ACCESSION NUMBER:		0001193125-24-177075
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240710
DATE AS OF CHANGE:		20240710

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276774
		FILM NUMBER:		241108827

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d865412d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774</FONT></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
February&nbsp;5, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g865412g0709220755922.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February&nbsp;5, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on July&nbsp;10, 2024 (the &#147;July 10, 2024 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have attached the
July&nbsp;10, 2024 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements the
information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction
with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On July&nbsp;9, 2024, the last reported sale price of
the ADSs on Nasdaq was $0.1920 per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk
Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently
filed reports and, if any, in any applicable prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is July&nbsp;10, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of July, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9745;&#8195;&#8195;&#8195;</FONT> Form <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;10, 2024, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press release titled, &#147;Kazia Therapeutics
Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma&#148;. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr.&nbsp;John
Friend contained in Exhibit 99.1, into the Company&#146;s registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224</FONT> and
<FONT STYLE="white-space:nowrap">333-276091).</FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated July&nbsp;10, 2024</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited </B>(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 10&nbsp;July 2024</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g829960g0710112747712.jpg" ALT="LOGO" STYLE="width:2.42083in;height:0.678472in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly
diagnosed unmethylated patients with glioblastoma </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, July&nbsp;10, 2024 &#151; Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused
drug development company, is pleased to announce results from <FONT STYLE="white-space:nowrap">GBM-AGILE,</FONT> a phase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma
(NCT03522298), a life-threatening brain cancer, where there is an urgent unmet need for new therapeutics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GBM AGILE STUDY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GBM AGILE is an adaptive phase II/III global trial sponsored by the Global Coalition for Adaptive Research (GCAR), a nonprofit organization comprised of some
of the world&#146;s foremost clinical, translational, and basic science researchers, from institutions such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. The trial is designed to efficiently screen for and characterize
the response of glioblastoma (GBM) patients to novel investigative agents. Utilizing a complex innovative design, Bayesian principles are applied to the primary endpoint (Overall Survival) comparison of the investigational agents to patients
receiving Standard of Care (SOC) enrolled from the study start (also referred to as cumulative control population). In general, secondary analyses and endpoints are assessed based on established statistical models in comparison to the control
patients enrolled at the same time as the investigational agent (concurrent control population). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib is the third drug candidate to complete its
evaluation in the study and was evaluated in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status as well as in patients with recurrent disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>GBM AGILE Paxalisib Results </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia CEO, Dr John
Friend stated, &#147;We are excited to have shown a 3.8 month improvement in overall survival, an approximate 33% improvement, for newly diagnosed unmethylated patients with GBM compared to the concurrent standard of care arm. Having comparable
Overall Survival data across two independent studies is a compelling outcome in this difficult to treat glioblastoma population. We look forward to discussing possible approaches for an accelerated approval pathway for paxalisib with the FDA.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A total of 313 newly diagnosed unmethylated (NDU) patients and recurrent patients being treated at top US cancer hospitals were randomized in Stage 1 to
either a paxalisib treatment arm (60 mg/day) or the SOC concurrent control arm from January 2021 to May 2022. The cumulative control arm was enrolled from July 2019 (GBM Agile study start date) to May 2022. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g829960g0710112747712.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the primary analysis the median Overall Survival (OS) was 14.77 months for paxalisib-treated NDU patients
(n=54) versus 13.84 months for cumulative SOC NDU patients (n=75). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a prespecified secondary analysis in the NDU patients, median OS was 15.54 months
in the paxalisib arm (n=54) versus 11.89 months for concurrent SOC (n=46). In addition, a prespecified sensitivity analysis in NDU patients showed similar median OS difference between paxalisib treated patients (15.54 months) and concurrent SOC
patients (11.70 months). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The secondary analysis results are consistent with the previously reported Company-sponsored phase II study, where median OS was
15.7 months (n=27) for paxalisib treated NDU patients compared to 12.7 months historically reported with temozolomide in this patient group (Wen 2022). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was well tolerated in <FONT STYLE="white-space:nowrap">GBM-AGILE,</FONT> and no new safety signals were identified in this patient population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An efficacy signal was not detected in the recurrent disease population (median OS of 9.69 months for concurrent SOC (n=113) versus 8.05 months for paxalisib
(n=100). Similar results in this population have been reported in the other two drug candidates that have completed the GBM AGILE trial. Kazia is currently pursuing further analyses of this data to elucidate potential signals for further
consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the totality of data available from all completed paxalisib clinical studies in newly diagnosed unmethylated GBM patients, Kazia
will request a meeting with the US Food&nbsp;&amp; Drug Administration (FDA) to discuss the results and determine if a potential path to accelerated approval is appropriate for paxalisib. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib has previously received orphan drug designation and fast track designation from the FDA for glioblastoma in unmethylated MGMT promoter status
patients, following radiation plus temozolomide therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Full data including secondary endpoints from the paxalisib arm of the GBM AGILE study is
expected to be presented at a scientific meeting later this year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Investors, please contact:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Media, please contact:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dr John Friend, CEO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>info@kaziatherapeutics.com</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>www.kaziatherapeutics.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Evelyn Yang</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Evelyn.yang@irdepartment.com.au</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">+61 432 871 726</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g829960g0710112747712.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms
of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a pivotal study in
glioblastoma, GBM AGILE, has been completed with presentation of paxalisib arm data expected later in 2024 at a major medical conference. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary
CNS lymphoma, with several of these trials having reported encouraging interim data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by
the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination
with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and
July 2022, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021.
Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study is ongoing and presentation of preliminary data at a medical conference is
anticipated in CY2024. For more information, please visit <U>www.kaziatherapeutics.com</U> or follow us on X @KaziaTx. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148;
&#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials and
investigator-initiated trials of Kazia&#146;s product candidates, the potential benefits of Kazia&#146;s product candidates, including paxalisib, and Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801. Such
statements are based on Kazia&#146;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those
anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions.
These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the United States Securities and Exchange Commission (SEC), and in subsequent filings
with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these
forward-looking statements, which apply only as of the date of this announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorized for release by Dr John Friend, CEO.
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g829960g0710112747712.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g829960g0710112747712.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  .4# 2(  A$! Q$!_\0
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?_,2P[22OL^W]:^8M%%%8G2%%%% !1110 &BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g865412g0709220755922.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g865412g0709220755922.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ -(# 2(  A$! Q$!_\0
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MN;\+3ZE,UP+PRM&,;3+G.?;-=)652'LY<IM0JJM!32M<**;(2L;,.H!->-^
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MV.AYZ&EN=/-S=PS-,0L3!PH49R/?K@]ZN44^>0.E!BT4E%0:"T4E% "T4E%
'"T4E% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
